The reaction of the organism's protection and defense systems in different populations vaccinated against Covid-19 is the main topic to be presented on the third and last day of the CoronaVac Symposium, an international online event held by Instituto Butantan with the support of Chinese biopharmaceutical company Sinovac between the 7th and 9th of December.
The vaccine's immunogenicity in the elderly and children based on phase 2 clinical trials will be discussed by Professor Hongjie Yu, School of Public Health, Fundan University, China. Researcher Susan Bueno, from Pontificia Universidad Católica de Chile, will discuss the efficacy and safety of the vaccine with inactivated SARS-CoV-2 virus among children in Chile. The topic will also be discussed by Sinovac's pharmacovigilance manager, Jiayi Wang.
Clinical trials being carried out by Sinovac in China indicate that the vaccine is safe for the population between three and 17 years of age and capable of inducing a high immune response. Of the 550 children and adolescents who participated in the study, 96% had antibodies 28 days after the second dose. Preliminary results from phase 3 reinforce that the immunizing agent is safe for this group.
The protection of the vaccine in people with comorbidities will be shown by the clinical director of the Hospital das Clínicas of the University of São Paulo Medical School (HCFMUSP), Eloisa Bonfá, especially among patients with autoimmune diseases. At the end of the session, researcher Zijie Zhang, from the Systems Biology Group at the State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan University, China, will present the efficacy and safety of CoronaVac in immunosuppressed and chronically ill patients.
On this day, the mediators of the discussions will be the professor of Biochemistry and Molecular Biology at the University of Barcelona, Rafael Franco, and the professor of clinical medicine at the University of São Paulo (USP), Paulo Andrade Lotufo. In the afternoon, there will be a round table with experts commenting on the main issues presented in the scientific sessions.
The CoronaVac Symposium will be held on the 7th, 8th and 9th of December, from 8:00 am to 11:00 am (Brasilia time). The international online event will feature the presence of Brazilian researchers and five other countries: Chile, Turkey, China, Spain and the United States.
The symposium will be opened by the president of Instituto Butantan, Dimas Covas, and by the president of Chinese biopharmaceutical company Sinovac, Weidong Yin.
Days: December 7, 8 and 9
Hours: from 8 am to 11 am